Kestrel Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors for cancers driven by KRAS mutations. The company focuses on creating best-in-class inhibitors that potently and selectively target oncogenic KRAS signaling, regardless of mutation or tumor type. Their lead candidate aims to disrupt GTP-mediated signaling to treat advanced, intractable cancers.
Funding
$7.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
RAS-driven cancers, characterized by mutations in the RAS gene family, account for over 30% of all cancers and are frequently resistant to existing therapies. These mutations, found across various RAS isoforms (KRAS, HRAS, and NRAS) and tumor histologies, represent a significant unmet need in oncology.
Solution
Kestrel Therapeutics is developing a new class of small molecule inhibitors designed to target pan-oncogenic RAS, regardless of RAS isoform, mutation, or tumor histology. These inhibitors bind directly to RAS proteins and inhibit their activation, effectively disrupting cancer cell signaling processes. By targeting RAS directly, Kestrel's approach aims to provide a broadly effective treatment for a wide range of RAS-driven cancers, including those with KRAS, HRAS, and NRAS mutations. The goal is to develop molecules capable of addressing all RAS mutations in all tumor types.
Target Audience
The primary target audience includes patients with RAS-driven cancers, such as pancreatic cancer, and the oncologists who treat them.
Features
- Potent inhibitors of pan-oncogenic RAS proteins
- Activity against KRAS, HRAS, and NRAS isoforms
- Direct binding to RAS proteins
- Inhibition of RAS protein activation